Genus plc

Stock factsheet

Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. We do not have a verified market capitalisation for this company.

Company profile

Genus is a British biotechnology company specialising in animal genetics, marketing genetically improved breeding animals and semen for cattle and pigs worldwide. The company uses genetic engineering and genomics to improve agricultural productivity and animal health. Genus supplies farmers and meat producers in numerous countries.

Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.

Comparable companies

Companies in the Biotech & Pharma sector of a similar size.

News timeline

1. 17.09.2026 Serial Production Over Innovation: The New Procurement Logic in Counter-UAS
2. 15.09.2026 Space Unicorns vs. Listed Small Caps: A Valuation Comparison
3. 15.09.2026 Engine License vs. Acquisition: What Vertical Integration Costs Defense Small Caps
4. 15.09.2026 Anthropic's Nasdaq IPO: What a Mega-Listing Means for AI Small Caps
5. 14.09.2026 Oil Price Shock as a Catalyst: What Cleantech Investors Must Really Check
6. 14.09.2026 AI Regulation: What Policy Frameworks Mean for Small-Cap Investors
7. 13.09.2026 Make-or-Buy in the Lab: AI Orchestration and Its Impact on Biotech Investors
8. 13.09.2026 OpenAI Stays Private: Liquidity Pressure on Listed AI Small Caps
9. 12.09.2026 National Hydrogen Quotas Phased Out: What EU-Wide Targets Mean for Project Finance
10. 12.09.2026 Board Appointments as IPO Signal: What AI Cloud Listings Really Need
11. 11.09.2026 Series F at $275M: What Orphan Gene Therapy Really Costs
12. 11.09.2026 Qualified Vendor Status: How Drone Procurement Selects Suppliers
13. 11.09.2026 Biotech Diversionary Pivots: Opportunity or Red Flag?
14. 09.09.2026 Decentralized Defense Production: What MBDA in Poland Means for Suppliers
15. 09.09.2026 FAA Certification as the Key: What Autonomous Cargo Aircraft Really Cost
16. 09.09.2026 Government Stakes in Quantum Computing: What $100M Deals Really Mean
17. 08.09.2026 mRNA Platform Logic: What Licensing and In-House Manufacturing Mean for Small Caps
18. 08.09.2026 Bankruptcy Before FDA Decision: When the Cash Runway Runs Out
19. 07.09.2026 First Launch & What Comes Next: How to Assess Orbital Small Caps
20. 06.09.2026 Niche Moats in Government Cybersecurity: What Investors Need to Know
21. 06.09.2026 After FDA Approval: When the Price Surge Raises New Questions
22. 05.09.2026 KDDX Destroyer: How Naval Turbine Contracts Move Defense Supplier Small Caps
23. 03.09.2026 Copyright Meets AI Training: What the U.S. Position Means for Data Providers
24. 02.09.2026 Reverse Merger vs. IPO: Three Paths to Market for Biotech Investors
25. 01.09.2026 Vertical Integration: When UAV Small Caps Acquire Their Suppliers
26. 31.08.2026 Import Barriers on Drones: How Trade Policy Is Splitting Supply Chains
27. 28.08.2026 Government Ransomware Attacks: How Federal Incidents Reshape the Cybersecurity Market
28. 27.08.2026 Radiation-Hardened Chips: Why On-Board Computers in Orbit Are Becoming Scarce
29. 27.08.2026 Pentagon Supply Chains: What Defense Framework Agreements Really Mean
30. 27.08.2026 Medical Technology Under Attack: What OT Security Means for Niche Providers
31. 26.08.2026 510(k) Pathway for AI Medical Devices: What an ECG Clearance Really Proves
32. 25.08.2026 Executive Orders & Quantum Stocks: What Political Tailwinds Actually Deliver
33. 25.08.2026 From Prototype to Series Contract: Defense Small Caps and Long Cycles
34. 25.08.2026 Pentagon Shoot-Offs: How Defense Small Caps Must Prove Themselves in Live Competition
35. 24.08.2026 Design Wins vs. AI Hype: What Really Sets Fabless Small Caps Apart
36. 22.08.2026 Gene Therapy Approvals: How Safety Incidents Reshape the Entire Sector
37. 22.08.2026 Q2 Quantum Computing Earnings: Real Turning Point or Just a Rally?
38. 21.08.2026 NSSTS Strategy Document: Which Technologies Enjoy Pentagon Priority
39. 21.08.2026 OpenAI IPO: How a Mega-IPO Is Reshaping the AI Ecosystem
40. 20.08.2026 Billion-Dollar Hypersonic Funding: What Castelion's Round Teaches Investors
41. 19.08.2026 AI Safety Infrastructure: What Sandbox Failures Mean for Investors
42. 18.08.2026 PLA Doctrine Shifts: What It Means for NATO Defense Small Caps
43. 18.08.2026 Neocloud Pivot: What Groq's Strategy Shift Reveals About AI Infrastructure
44. 15.08.2026 Military Energy Gap: How Drone Fleets Are Overwhelming Power Supply
45. 11.08.2026 Event Windows in Space Stocks: Volatility Without a Change in Value
46. 11.08.2026 Narrative vs. Fundamentals: What QUBT Investors Underestimate
47. 11.08.2026 IBM's Quantum Horizon: What a Tech Giant's Timeline Means for Pure-Play Providers
48. 11.08.2026 Licensing Deal or Acquisition? How Strong Trial Data Shift Biotech Power Dynamics
49. 11.08.2026 When Big Tech Sets the Direction: Niches for Small-Cap Investors
50. 11.08.2026 Optical Laser Links in Space: From Demo to Business Model
51. 11.08.2026 IDIQ Contracts & Loitering Munition: What Drone Orders Really Mean
52. 11.08.2026 Dosing Interval in Phase 2: What Biotech Investors Really Need to Check
53. 11.08.2026 Foundation Models in Cybersecurity: Who Wins the AI Defense Race?
54. 09.08.2026 AI Agents Out of Control: Containment as a New Competitive Differentiator
55. 09.08.2026 Biotech IPOs: What an IPO Window Means for Small-Cap Investors
56. 09.08.2026 When AI Becomes a Cyberweapon: What Security Thresholds Mean
57. 07.08.2026 EU Subsidies for Hydrogen: Opportunity and Dependency at Once
58. 07.08.2026 IRIS² Mega-Program: How Framework Agreements Move Small-Cap Suppliers
59. 07.08.2026 Rising Revenue, Falling Stock: What the Rigetti Paradox Teaches Investors
60. 07.08.2026 Design-Win to Volume Order: How Fabless Chip Designers Work
61. 07.08.2026 Counter-Drone Procurement: When Price Rewrites the Rules of Competition
62. 07.08.2026 Composite Endpoints: When Trial Data Can Be Misleading
63. 06.08.2026 Cybersecurity IPO on the ASX: What Investors Need to Know About Stock Exchanges
64. 06.08.2026 Reading Clinical Biotech Q2 Reports: How to Decode the Catalyst Calendar
65. 06.08.2026 SAR Satellite Contracts: How the NRO Evaluates Small Space Companies
66. 06.08.2026 AI Monetization in Small Caps: ARR, Margins, and Real Contracts
67. 05.08.2026 Quantum Computing Stocks: How to Read Burn Rate Before Q2 Earnings
68. 05.08.2026 AI Regulation: What the U.S. Testing Framework Means for Open Models
69. 05.08.2026 When Infrastructure Becomes an AI Business Model: What Investors Need to Know
70. 05.08.2026 Government Contracts as Growth Engines: What Defense Orders Mean for Space Small Caps
71. 05.08.2026 Biotech M&A: When Small Caps Become Acquisition Targets
72. 05.08.2026 Hughes Bankruptcy: What LEO Disruption Means for Satellite Investors
73. 05.08.2026 Satellite Propulsion for Defense: How Small Caps Benefit from the Defense Boom
74. 05.08.2026 Quantum Small Caps: When Tech Milestones Don't Equal Revenue
75. 05.08.2026 When a Space Company Becomes a Data Center Operator: Lessons for Small-Cap Investors
76. 05.08.2026 Defense Contracts as a Revenue Base for Satellite Small Caps
77. 04.08.2026 Rocketdyne Spinout: What PE-Driven Carve-Outs Mean for the Space Sector
78. 04.08.2026 Satellite Propulsion: How Military Demand Shapes a Small-Cap Niche
79. 03.08.2026 Government Satellite Contracts: What Demo Deals Mean for Space Small Caps
80. 03.08.2026 AI Security Validation: What Valuation Jumps Really Mean
81. 03.08.2026 IND Process & FDA Trialblazer: What Changes for Biotech Small Caps
82. 03.08.2026 Defense Contracts in Space: Large Corp vs. Start-Up — What Investors Should Know
83. 03.08.2026 Continuous Validation: How AI Is Reshaping the Cybersecurity Market
84. 03.08.2026 Laser Communication in Orbit: What Demonstration Contracts Mean for Space Small Caps
85. 03.08.2026 AI-Powered Security Validation: Continuous Monitoring Replaces the Annual Pentest
86. 03.08.2026 Demonstration Contracts in Orbit: What Navy Awards Mean for Space Start-Ups
87. 03.08.2026 Revenue Guidance Upgrade After Approval: What It Means for Biotech Investors
88. 03.08.2026 Pivotal Trials in Oncology: What Phase 2/3 Data Really Mean
89. 02.08.2026 AI Copyright: When Training Data Becomes a Liability Risk
90. 01.08.2026 Laser Communication in Orbit: What Military Contracts Mean for Space Small Caps
91. 31.07.2026 SRAM in the AI Era: How Niche Chips Promise Data Center Returns
92. 30.07.2026 Defense IPO Postponed: What Really Drives Valuation Expectations
93. 29.07.2026 Defense IPO Timing: Why Strong Order Backlogs Aren't Enough
94. 28.07.2026 GLP-1 for Addiction: What Phase II Trial Data Really Promise
95. 27.07.2026 FDA Reviewers vs. Sponsor: When Regulators and Biotech Read Data Differently
96. 24.07.2026 Quantum Correction: Valuation Reset or Fundamental Breakdown?
97. 23.07.2026 Megacap Acquisitions in the Quantum Market: Opportunity or Displacement?
98. 22.07.2026 Framework Agreement or Firm Order? How Small-Cap Investors Read AI Deals
99. 20.07.2026 Dilution in Quantum Small Caps: How to Read a Capital Increase
100. 17.07.2026 Pump-and-Dump: How Regulation Dried Up Micro-Cap IPOs
101. 16.07.2026 Russell 2000 at Record High: Macro Signals for Small-Cap Investors
102. 15.07.2026 AI Platform Pressure: How Cybersecurity Small Caps Defend Their Niche
103. 13.07.2026 Micro-Cap Biotech: What Really Drives Share Price Losses
104. 09.07.2026 Hong Kong IPO Market: When Megadeals Crowd Out Small-Cap Listings
105. 08.07.2026 AI Infrastructure Small Caps: ARR, Margins, and Concentration Risk
106. 30.07.2026 Quantum Computing Stocks: When One Contract Moves the Market
107. 30.07.2026 FDA Adcom: What a Negative Vote Costs Biotech Investors
108. — Biotech IPOs 2026: What an Open IPO Window Really Means

Investor Relations

We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.

Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.